guest ::
| Home > Publications database > Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. > print |
| Home > Publications database > Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. > print |
| 001 | 286750 | ||
| 005 | 20241120141324.0 | ||
| 024 | 7 | _ | |a 10.1186/s12943-023-01919-3 |2 doi |
| 024 | 7 | _ | |a pmid:38200602 |2 pmid |
| 024 | 7 | _ | |a altmetric:158503400 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00082 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Schmäche, Tim |b 0 |
| 245 | _ | _ | |a Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. |
| 260 | _ | _ | |a London |c 2024 |b Biomed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705391315_10784 |2 PUB:(DE-HGF) |x Letter |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:D120# / Correspondence |
| 520 | _ | _ | |a This study sought to determine the value of patient-derived organoids (PDOs) from esophago-gastric adenocarcinoma (EGC) for response prediction to neoadjuvant chemotherapy (neoCTx).Endoscopic biopsies of patients with locally advanced EGC (n = 120) were taken into culture and PDOs expanded. PDOs' response towards the single substances of the FLOT regimen and the combination treatment were correlated to patients' pathological response using tumor regression grading. A classifier based on FLOT response of PDOs was established in an exploratory cohort (n = 13) and subsequently confirmed in an independent validation cohort (n = 13).EGC PDOs reflected patients' diverse responses to single chemotherapeutics and the combination regimen FLOT. In the exploratory cohort, PDOs response to single 5-FU and FLOT combination treatment correlated with the patients' pathological response (5-FU: Kendall's τ = 0.411, P = 0.001; FLOT: Kendall's τ = 0.694, P = 2.541e-08). For FLOT testing, a high diagnostic precision in receiver operating characteristic (ROC) analysis was reached with an AUCROC of 0.994 (CI 0.980 to 1.000). The discriminative ability of PDO-based FLOT testing allowed the definition of a threshold, which classified in an independent validation cohort FLOT responders from non-responders with high sensitivity (90%), specificity (100%) and accuracy (92%).In vitro drug testing of EGC PDOs has a high predictive accuracy in classifying patients' histological response to neoadjuvant FLOT treatment. Taking into account the high rate of successful PDO expansion from biopsies, the definition of a threshold that allows treatment stratification paves the way for an interventional trial exploring PDO-guided treatment of EGC patients. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Gastric cancer |2 Other |
| 650 | _ | 7 | |a Patient-derived organoids |2 Other |
| 650 | _ | 7 | |a Personalized medicine |2 Other |
| 650 | _ | 7 | |a Response prediction |2 Other |
| 700 | 1 | _ | |a Fohgrub, Juliane |b 1 |
| 700 | 1 | _ | |a Klimova, Anna |b 2 |
| 700 | 1 | _ | |a Laaber, Karin |0 P:(DE-He78)2edb00bc9fd4fe7c858c2838ce1c0024 |b 3 |
| 700 | 1 | _ | |a Drukewitz, Stephan |b 4 |
| 700 | 1 | _ | |a Merboth, Felix |b 5 |
| 700 | 1 | _ | |a Hennig, Alexander |b 6 |
| 700 | 1 | _ | |a Seidlitz, Therese |b 7 |
| 700 | 1 | _ | |a Herbst-Nowrouzi, Friederike |0 P:(DE-He78)13dc15153ce40f775007112548f34d79 |b 8 |u dkfz |
| 700 | 1 | _ | |a Baenke, Franziska |b 9 |
| 700 | 1 | _ | |a Ada, Anne-Marlen |b 10 |
| 700 | 1 | _ | |a Groß, Thomas |0 P:(DE-He78)196be4790a587c09c4e13d8f91adcaa1 |b 11 |u dkfz |
| 700 | 1 | _ | |a Wenzel, Carina |b 12 |
| 700 | 1 | _ | |a Ball, Claudia |0 P:(DE-He78)7a10ea1b9b2872da9f375002c44ddfce |b 13 |u dkfz |
| 700 | 1 | _ | |a Praetorius, Christian |b 14 |
| 700 | 1 | _ | |a Schmidt, Thomas |b 15 |
| 700 | 1 | _ | |a Ringelband-Schilling, Barbara |b 16 |
| 700 | 1 | _ | |a Koschny, Ronald |b 17 |
| 700 | 1 | _ | |a Stenzinger, Albrecht |b 18 |
| 700 | 1 | _ | |a Roeder, Ingo |b 19 |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 20 |u dkfz |
| 700 | 1 | _ | |a Zeissig, Sebastian |b 21 |
| 700 | 1 | _ | |a Welsch, Thilo |b 22 |
| 700 | 1 | _ | |a Aust, Daniela |b 23 |
| 700 | 1 | _ | |a Glimm, Hanno |0 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9 |b 24 |u dkfz |
| 700 | 1 | _ | |a Folprecht, Gunnar |b 25 |
| 700 | 1 | _ | |a Weitz, Jürgen |b 26 |
| 700 | 1 | _ | |a Haag, Georg Martin |0 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d |b 27 |e Last author |u dkfz |
| 700 | 1 | _ | |a Stange, Daniel E |b 28 |
| 773 | _ | _ | |a 10.1186/s12943-023-01919-3 |g Vol. 23, no. 1, p. 10 |0 PERI:(DE-600)2091373-4 |n 1 |p 10 |t Molecular cancer |v 23 |y 2024 |x 1476-4598 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/286750/files/s12943-023-01919-3.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/286750/files/s12943-023-01919-3.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:286750 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)2edb00bc9fd4fe7c858c2838ce1c0024 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)13dc15153ce40f775007112548f34d79 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)196be4790a587c09c4e13d8f91adcaa1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)7a10ea1b9b2872da9f375002c44ddfce |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL CANCER : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T09:06:41Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T09:06:41Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T09:06:41Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 30 |0 StatID:(DE-HGF)9930 |2 StatID |b MOL CANCER : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-24 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-24 |
| 920 | 2 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l D120 Angewandte Tumor-Immunität |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B280-20160331 |k B280 |l B280 Translationale funktionelle Krebsgenomik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)DD01-20160331 |k DD01 |l DKTK Koordinierungsstelle Dresden |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l D120 Angewandte Tumor-Immunität |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B280-20160331 |
| 980 | _ | _ | |a I:(DE-He78)DD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|